You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0302 Validation of Highly Sensitive Flow Cytometry as A Biomarker for Rituximab in Sle: A Rationale for More Intensive Treatment To Improve Clinical Outcomes

Alerts

Article menu
Download PDFPDF
Poster Presentations
SLE, Sjögren's and APS - treatment
THU0302 Validation of Highly Sensitive Flow Cytometry as A Biomarker for Rituximab in Sle: A Rationale for More Intensive Treatment To Improve Clinical Outcomes
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address